Walking Fish Therapeutics
The business, the turning points, and the decisions behind them.
01 / WHAT IT BUILT
B-cell-based therapeutic development
Walking Fish Therapeutics developed therapies based on engineered B cells for Fabry disease and other medical conditions.
02 / Walking Fish Therapeutics FAILURE REASONS
Failure reasons
Founder Rusty Williams said an existing investor withdrew a commitment to the Series B, citing debt tied to a multiyear property lease; another investor then withdrew. The company could not replace them in time to fund its planned early clinical study and was advised to close. This is the founder’s explanation, not a finding that the therapy failed in clinical trials.
03 / EVENT HISTORY
Events in the structured record
- Investors withdrew during financing
The founder described withdrawals around a March board meeting as the financing round was being assembled.
- Closure confirmed
A 7 May report relayed the founder’s confirmation that the company had shuttered before its intended first clinical trial.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN
How the factors connect
- 01
Clinical study needed Series B capital
- 02
Investors withdrew commitments
- 03
Replacement funding could not be secured in time
- 04
Company closed before intended clinical trial